v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Non-Controlling Interest (“NCI”)
Beginning balance (in shares) at Dec. 31, 2024   153,206        
Beginning balance at Dec. 31, 2024 $ 126,256 $ 15 $ 512,022 $ (383,822) $ (1,896) $ (63)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   3        
Exercise of stock options 2   2      
Stock-based compensation 18,260   18,260      
Vesting of restricted stock units (“RSUs”) (in shares)   5,178        
Vesting of restricted stock units (“RSUs”) 1 $ 1        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement (in shares)   2,302        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement 1,866   1,866      
Accretion of Redeemable NCI 0          
Short-swing profit recovery 24   24      
Net loss (56,106)     (56,063)   (43)
Actuarial gain (loss) on pension 235       235  
Foreign currency translation (loss) gain (239)       (239)  
Reallocation of NCI due to forfeiture 0   (79)     79
Ending balance (in shares) at Jun. 30, 2025   160,689        
Ending balance at Jun. 30, 2025 90,299 $ 16 532,095 (439,885) (1,900) (27)
Beginning balance (in shares) at Mar. 31, 2025   154,243        
Beginning balance at Mar. 31, 2025 114,913 $ 15 521,322 (404,958) (1,365) (101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   3        
Exercise of stock options 2   2      
Stock-based compensation 8,984   8,984      
Vesting of restricted stock units (“RSUs”) (in shares)   4,141        
Vesting of restricted stock units (“RSUs”) 1 $ 1        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement (in shares)   2,302        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement 1,866   1,866      
Accretion of Redeemable NCI 0          
Net loss (34,932)     (34,927)   (5)
Actuarial gain (loss) on pension (276)       (276)  
Foreign currency translation (loss) gain (259)       (259)  
Reallocation of NCI due to forfeiture 0   (79)     79
Ending balance (in shares) at Jun. 30, 2025   160,689        
Ending balance at Jun. 30, 2025 $ 90,299 $ 16 532,095 (439,885) (1,900) (27)
Beginning balance (in shares) at Dec. 31, 2025 168,969 168,969        
Beginning balance at Dec. 31, 2025 $ 67,460 $ 17 555,873 (487,433) (966) (31)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares) 568 568        
Exercise of stock options $ 976   976      
Exercise of warrants (in shares)   855        
Exercise of warrants 1 $ 1        
Stock-based compensation 11,419   11,419      
Vesting of restricted stock units (“RSUs”) (in shares)   5,841        
Vesting of restricted stock units (“RSUs”) (3,421)   (3,421)      
Shares issued per Convertible Debentures (in shares)   2,986        
Shares issued per Convertible Debentures 13,754   13,754      
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement (in shares)   721        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement 3,769   3,769      
Purchase of capped calls (20,460)   (20,460)      
Paid-in-kind (“PIK”) distributions to redeemable non-controlling interest (“Redeemable NCI”) (2,172)   (2,172)      
Accretion of Redeemable NCI (2,423)   (2,423)      
Net loss (62,177)     (62,177)   0
Actuarial gain (loss) on pension (54)       (54)  
Foreign currency translation (loss) gain $ 185       185  
Ending balance (in shares) at Jun. 30, 2026 179,940 179,940        
Ending balance at Jun. 30, 2026 $ 6,857 $ 18 557,315 (549,610) (835) (31)
Beginning balance (in shares) at Mar. 31, 2026   174,147        
Beginning balance at Mar. 31, 2026 30,458 $ 17 551,026 (519,918) (636) (31)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   525        
Exercise of stock options 942   942      
Exercise of warrants (in shares)   515        
Exercise of warrants 1 $ 1        
Stock-based compensation 4,366   4,366      
Vesting of restricted stock units (“RSUs”) (in shares)   3,700        
Vesting of restricted stock units (“RSUs”) (1,672)   (1,672)      
Shares issued per Convertible Debentures (in shares)   332        
Shares issued per Convertible Debentures 1,317   1,317      
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement (in shares)   721        
Shares issued under the at-the-market (“ATM”) program, net of issuance costs/ Shares issued per equity purchase agreement 3,769   3,769      
Paid-in-kind (“PIK”) distributions to redeemable non-controlling interest (“Redeemable NCI”) (1,096)   (1,096)      
Accretion of Redeemable NCI (1,337)   (1,337)      
Net loss (29,692)     (29,692)    
Actuarial gain (loss) on pension 62       62  
Foreign currency translation (loss) gain $ (261)       (261)  
Ending balance (in shares) at Jun. 30, 2026 179,940 179,940        
Ending balance at Jun. 30, 2026 $ 6,857 $ 18 $ 557,315 $ (549,610) $ (835) $ (31)